<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="addendum" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Bacteriophage</journal-id>
<journal-id journal-id-type="iso-abbrev">Bacteriophage</journal-id>
<journal-id journal-id-type="publisher-id">KBAC</journal-id>
<journal-id journal-id-type="publisher-id">kbac20</journal-id>
<journal-title-group>
<journal-title>Bacteriophage</journal-title>
</journal-title-group>
<issn pub-type="ppub">2159-7073</issn>
<issn pub-type="epub">2159-7081</issn>
<publisher>
<publisher-name>Taylor &amp; Francis</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28090385</article-id>
<article-id pub-id-type="pmc">5221744</article-id>
<article-id pub-id-type="publisher-id">1251380</article-id>
<article-id pub-id-type="doi">10.1080/21597081.2016.1251380</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Addenda</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fecal microbiota transplantation to fight <italic>Clostridium difficile</italic> infections and other intestinal diseases</article-title>
<alt-title alt-title-type="running-authors">K. Moelling and F. Broecker</alt-title>
<alt-title alt-title-type="running-title">Bacteriophage</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Moelling</surname>
<given-names>Karin</given-names>
</name>
<xref ref-type="aff" rid="af0001">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Broecker</surname>
<given-names>Felix</given-names>
</name>
<xref ref-type="aff" rid="af0001">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="af0003">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="af0004">
<sup>d</sup>
</xref>
<xref ref-type="corresp" rid="an0001"></xref>
</contrib>
<aff id="af0001"><label>a</label><institution>Max Planck Institute for Molecular Genetics</institution>, Berlin, <country>Germany</country></aff>
<aff id="af0002"><label>b</label><institution>Institute for Medical Microbiology, Unversity of Zürich</institution>, Zürich, <country>Switzerland</country></aff>
<aff id="af0003"><label>c</label><institution>Max Planck Institute of Colloids and Interfaces</institution>, Potsdam, <country>Germany</country></aff>
<aff id="af0004"><label>d</label><institution>Department of Microbiology, Icahn School of Medicine at Mount Sinai</institution>, New York, NY, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="an0001"><bold>CONTACT</bold> Felix Broecker <email xlink:href="felixbroecker@gmx.net">felixbroecker@gmx.net</email><institution>Department of Microbiology, Icahn School of Medicine at Mount Sinai</institution>, <addr-line>1 Gustave L. Levy Pl</addr-line>, New York, NY 10029, <country>USA</country></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>21</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>6</volume>
<issue>4</issue>
<elocation-id seq="5">e1251380</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>13</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>10</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 Taylor &amp; Francis</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>Taylor &amp; Francis</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="kbac-06-04-1251380.pdf"></self-uri>
<related-article ext-link-type="doi" id="d37e161" related-article-type="addended-article" xlink:href="10.1111/nyas.13100">Addendum to: <person-group person-group-type="author"><name name-style="western"><surname>Broecker</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Klumpp</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Moelling</surname><given-names>K</given-names></name></person-group>. <article-title>Long-term microbiota and virome in a Zürich patient after fecal transplantation against Clostridium difficile infection</article-title>. <source/>Ann N Y Acad Sci
<year>2016</year>. http://dx.doi.org/<pub-id pub-id-type="doi">10.1111/nyas.13100</pub-id>.</related-article>
<abstract>
<title>ABSTRACT</title>
<p>We have analyzed fecal bacterial and viral communities of a patient with recurrent <italic>C. difficile</italic> infection (rCDI) who was cured by fecal microbiota transplantation (FMT). The “Zürich Patient” experienced immediate cure and has remained free of symptoms for now over 5 y. Donor-similar bacterial compositions after 4.5 y post-FMT demonstrated sustainable engraftment of donor microbiota predominated by <italic>Bacteroidetes</italic> and <italic>Firmicutes</italic> bacteria. Appearance of beneficial species <italic>Faecalibacterium prausnitzii</italic> and <italic>Akkermansia municiphila</italic> was detected while disease-related <italic>Proteobacteria</italic> decreased. Stabilization of the microbiota took longer than expected from the rapidly improving clinical symptoms, suggesting the need for longer-lasting patient observation. The virome was mainly composed of <italic>Caudovirales</italic> bacteriophages but surprisingly also contained sequences related to a <italic>Chlorella</italic> giant virus that normally infects green algae not known to inhabitate the human intestine. FMT is highly effective against rCDI and is presently broadening its application to other conditions including inflammatory bowel disease (IBD). Here, we discuss the prospects and challenges of FMT against rCDI and other indications including a focus on bacteriophages.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>KEYWORDS</title>
<kwd><italic>Chlorella</italic> giant virus</kwd>
<kwd>clinical trial</kwd>
<kwd>
<italic>Clostridium difficile</italic>
</kwd>
<kwd>fecal microbiota transplantation</kwd>
<kwd>microbiota</kwd>
<kwd>phage therapy</kwd>
<kwd>virome</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<ref-count count="30"></ref-count>
<page-count count="8"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>